Correspondence 0001104659-25-124218 from Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc.
Date: Dec. 23, 2025 · CIK: 0001781983 · Accession: 0001104659-25-124218
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292286
Letter
December 23, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attention: Chris Edwards
Re: Aprea Therapeutics, Inc.
Registration Statement on Form S-3 Filed December 19, 2025 File No. 333-292286 Acceleration Request Requested Date: December 29, 2025 Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-292286) (the " Registration Statement ") be declared effective on the "Requested Date" at the "Requested Time" set forth above, or as soon as practicable thereafter.
We request that we be notified of the effectiveness of the Registration Statement by telephone to Patrick O'Malley of DLA Piper LLP (US) at 858.677.1471. Thank you for your assistance.
Very truly yours,
Aprea Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm December 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Chris Edwards Re: Aprea Therapeutics, Inc. Registration Statement on Form S-3 Filed December 19, 2025 File No. 333-292286 Acceleration Request Requested Date: December 29, 2025 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-292286) (the " Registration Statement ") be declared effective on the "Requested Date" at the "Requested Time" set forth above, or as soon as practicable thereafter. We request that we be notified of the effectiveness of the Registration Statement by telephone to Patrick O'Malley of DLA Piper LLP (US) at 858.677.1471. Thank you for your assistance. Very truly yours, Aprea Therapeutics, Inc. /s/ John Hamill John Hamill Chief Financial Officer cc: Oren Gilad (Chief Executive Officer; Aprea Therapeutics, Inc.) Patrick O'Malley (DLA Piper LLP (US))